RxDoctor Payments DataLook up a doctor →

Frank Hull, MD

Pulmonary Disease · Plantation, FLNPI 1407832744

Payments from drug & device makers

$1,164,247in general payments, 2019–2025

Across 835 payments — averaging $1394.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$393K
  • AstraZeneca$387K
  • Sanofi US Services Inc.$311K
  • Insmed, Inc.$28K
  • Roche Products Limited$18K
  • Astrazeneca UK Limited$11K
  • plus $18K from 51 others
$10,175in research payments, 2019–2025

Across 17 payments — averaging $598.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Actelion Pharmaceuticals US, Inc.$7K
  • Actelion Pharmaceuticals, Ltd$3K
  • GSK$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK175$392,712
AstraZeneca(2 entities)134$386,566
Sanofi US Services Inc.23$311,206
Insmed, Inc.114$27,775
Roche Products Limited4$17,799
Astrazeneca UK Limited4$10,627
Intuitive Surgical8$4,056
AbbVie(2 entities)7$1,908
Actelion Pharmaceuticals US, Inc.35$1,821
Actelion Pharmaceuticals, Ltd1$900
Mylan Specialty L.p.36$824
Regeneron Healthcare Solutions, Inc.26$728
Mallinckrodt Hospital Products Inc.22$697
Harmony Biosciences LLC18$611
Boehringer Ingelheim23$601
Bayer13$596
Paratek Pharmaceuticals, Inc.24$429
Amgen15$331
Pinnacle Biologics, Inc2$312
United Therapeutics Corporation15$302
Sanofi9$292
Astellas Pharma US Inc7$289
Jazz Pharmaceuticals Inc.15$283
Takeda Pharmaceuticals U.S.A., Inc.9$254
Pfizer13$251
Merck8$185
Viatris Specialty LLC6$144
Inspire Medical Systems, Inc.1$133
Grifols USA, LLC7$127
Melinta Therapeutics, LLC5$125
Fisher & Paykel Healthcare Inc2$117
Philips North America LLC9$117
Verona Pharma, Inc.1$117
Genentech USA, Inc.6$98
Electromed, Inc.4$88
Kerecis Limited2$86
ANI Pharmaceuticals, Inc.2$81
Axsome Therapeutics, Inc.3$79
Teva Pharmaceuticals USA, Inc.2$53
Gilead2$52
Sunovion Pharmaceuticals Inc.2$46
Mallinckrodt Enterprises LLC2$45
Shionogi Inc2$43
Veran Medical Technologies, Inc.2$41
Baxter Healthcare2$39
La Jolla Pharmaceutical Company2$36
Medtronic1$33
Vifor Pharma, Inc.1$32
Inogen, Inc.1$24
Phadia US Inc.1$21
Shire North American Group Inc1$20
Sandoz1$19
Novartis1$16
Circassia Inc.1$16
Nabriva Therapeutics, PLC1$15
Johnson & Johnson1$14
Covidien LP1$14

How this compares

$1,164,247 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Medicare billing

Part B allowed, 2024
$139,220
Medicare patients
325
Services billed
1,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Plantation

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →